The first-ever drug based on the gene-silencing technique known as RNA interference had an underwhelming first quarter of sales — but the company that brought it to market is encouraging investors to withhold judgement.

Alnylam (ALNY) said Wednesday that the drug, Onpattro, brought in less than $500,000 during the third quarter. The company has a steep hill to climb if it is to eventually become a $1 billion blockbuster, as analysts have widely suggested it might someday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy